EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

LATE-NC Stage 3: a diagnostic rubric to differentiate severe LATE-NC from FTLD-TDP

Ryan K Shahidehpour, Yuriko Katsumata, Dennis W Dickson, Nikhil B Ghayal, Khine Zin Aung, Xian Wu, Panhavuth Phe, Gregory A Jicha, Allison M Neltner, Jessalin R C Archer, Maria M Corrada, Claudia H Kawas und 6 weitere

Acta Neuropathologica · 2025

DOI: 10.1007/s00401-025-02876-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, 2025. Verfasst von Ryan K Shahidehpour und 17 weiteren Autor:innen. Beteiligte Einrichtung: Sanders-Brown Center On Aging, University of Kentucky, Rm 575 Lee Todd Jr Bldg/U. Kentucky, 789 S. Limestone Ave, Lexington, KY, 40536, USA. Hauptthemen laut MEDLINE: Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Brain. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIMH NIH HHS, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A diagnostic rubric is required to distinguish between limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). In LATE-NC Stage 3, TDP-43 proteinopathy is present in the middle frontal gyrus (MFG), thus posing a potential diagnostic challenge in differentiating these severe LATE-NC cases from FTLD-TDP. LATE-NC Stage 3 cases and other TDP-43 proteinopathies were analyzed from the University of Kentucky (total n = 514 with TDP-43 pathology assessed), The 90+ Study at the University of California Irvine (n = 458), and the Mayo Clinic (n = 5067) brain banks. Digital pathology was used to quantify pathology burden in a select subset of cases (n = 51), complemented by a previously-described manual counting method and expert neuropathologic examinations to evaluate qualitative features such as FTLD-TDP types and subtypes of neuronal cytoplasmic inclusions (NCIs). To evaluate clinical and genetic characteristics of LATE-NC Stage 3, data were analyzed from the National Alzheimer's Coordinating Center (NACC) Neuropathology Data set and correlated with findings from the Alzheimer's Disease Genetics Consortium (ADGC). When using TDP-43 proteinopathy quantification in the MFG as a diagnostic criterion, more than 90% of cases could be classified as either LATE-NC Stage 3 or FTLD-TDP. Diagnostically challenging scenarios included a subset of FTLD-TDP Type B cases with relatively mild MFG TDP-43 pathology and a novel non-LATE-NC, non-FTLD-TDP pathologic subtype with severe MFG TDP-43 pathology. Taking these potential pitfalls into account, a classification schema was developed that could correctly diagnose all included cases. There was no difference in the Alzheimer's disease pathological load in LATE-NC Stages 2 versus 3. In genetic analyses, the GRN (rs5848) risk allele was preferentially associated with LATE-NC Stage 3, whereas TMEM106B and APOE risk-associated variants were not. In conclusion, LATE-NC Stage 3 could be differentiated reliably from FTLD-TDP and other TDP-43-opathies, based on a data-driven diagnostic rubric.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Frontotemporal Lobar DegenerationTDP-43 ProteinopathiesBrainHumansMaleFemaleAgedDiagnosis, DifferentialAged, 80 and overDNA-Binding ProteinsMiddle AgedInclusion BodiesDementia

Stichwörter der Autor:innen

ALSARTAGFTLD-MNDLNTScanScopers1990622

Substanzen

DNA-Binding ProteinsTARDBP protein, human

Autor:innen und Institutionen

  • Sanders-Brown Center On Aging, University of Kentucky, Rm 575 Lee Todd Jr Bldg/U. Kentucky, 789 S. Limestone Ave, Lexington, KY, 40536, USA.
  • Department of Neuroscience, University of Kentucky, Lexington, KY, USA.
  • Department of Biostatistics, University of Kentucky, Lexington, KY, 40536, USA.
  • Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
  • Department of Neurology, University of Kentucky, Lexington, KY, 40536, USA.
  • Department of Neurology, University of California, Irvine, CA, USA.

Förderung

  • NIA NIH HHS
  • NIMH NIH HHS
  • NHGRI NIH HHS
  • National Institutes on Health, United States
  • NINDS NIH HHS
  • NCRR NIH HHS
  • NCI NIH HHS
  • Wellcome Trust

Zitieren

APA

Shahidehpour, R. K., Katsumata, Y., Dickson, D. W., Ghayal, N. B., Aung, K. Z., Wu, X., Phe, P., Jicha, G. A., Neltner, A. M., Archer, J. R. C., Corrada, M. M., Kawas, C. H., Ahmad Sajjadi, S., Woodworth, D. C., Bukhari, S. A., Montine, T. J., Fardo, D. W., & Nelson, P. T. (2025). LATE-NC Stage 3: a diagnostic rubric to differentiate severe LATE-NC from FTLD-TDP. Acta Neuropathologica. https://doi.org/10.1007/s00401-025-02876-5

Vancouver

Shahidehpour RK, Katsumata Y, Dickson DW, Ghayal NB, Aung KZ, Wu X, et al. LATE-NC Stage 3: a diagnostic rubric to differentiate severe LATE-NC from FTLD-TDP. Acta Neuropathologica. 2025. doi:10.1007/s00401-025-02876-5

BibTeX
@article{Shahidehpour2025,
  author = {Shahidehpour, Ryan K and Katsumata, Yuriko and Dickson, Dennis W and Ghayal, Nikhil B and Aung, Khine Zin and Wu, Xian and Phe, Panhavuth and Jicha, Gregory A and Neltner, Allison M and Archer, Jessalin R C and Corrada, Maria M and Kawas, Claudia H and Ahmad Sajjadi, S and Woodworth, Davis C and Bukhari, Syed A and Montine, Thomas J and Fardo, David W and Nelson, Peter T},
  title = {LATE-NC Stage 3: a diagnostic rubric to differentiate severe LATE-NC from FTLD-TDP},
  journal = {Acta Neuropathologica},
  year = {2025},
  doi = {10.1007/s00401-025-02876-5}
}
Kostenlos starten →